Literature DB >> 18223165

B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells.

Takeshi Azuma1, Sheng Yao, Gefeng Zhu, Andrew S Flies, Sarah J Flies, Lieping Chen.   

Abstract

B7-H1 is an immunoglobulin-like immune suppressive molecule broadly detectable on the majority of human and rodent cancers, and its functions have been attributed to delivering an inhibitory signal to its counter-receptor programmed death-1 (PD-1) on T cells. Here we report that B7-H1 on cancer cells receives a signal from PD-1 to rapidly induce resistance against T cell-mediated killing because crippling signaling capacity of B7-H1 but not PD-1 ablates this resistance. Importantly, loss of B7-H1 signaling is accompanied by increased susceptibility to immune-mediated tumoricidal activity. In addition to resistance against T-cell destruction, B7-H1+ cancer cells also become refractory to apoptosis induced by Fas ligation or the protein kinase inhibitor Staurosporine. Our study reveals a new mechanism by which cancer cells use a receptor on immune cells as a ligand to induce resistance to therapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18223165      PMCID: PMC2275025          DOI: 10.1182/blood-2007-11-123141

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  30 in total

1.  B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion.

Authors:  H Dong; G Zhu; K Tamada; L Chen
Journal:  Nat Med       Date:  1999-12       Impact factor: 53.440

2.  PD-L2 is a second ligand for PD-1 and inhibits T cell activation.

Authors:  Y Latchman; C R Wood; T Chernova; D Chaudhary; M Borde; I Chernova; Y Iwai; A J Long; J A Brown; R Nunes; E A Greenfield; K Bourque; V A Boussiotis; L L Carter; B M Carreno; N Malenkovich; H Nishimura; T Okazaki; T Honjo; A H Sharpe; G J Freeman
Journal:  Nat Immunol       Date:  2001-03       Impact factor: 25.606

3.  Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors.

Authors:  Ryan A Wilcox; Dallas B Flies; Gefeng Zhu; Aaron J Johnson; Koji Tamada; Andrei I Chapoval; Scott E Strome; Larry R Pease; Lieping Chen
Journal:  J Clin Invest       Date:  2002-03       Impact factor: 14.808

4.  Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice.

Authors:  Taku Okazaki; Yoshimasa Tanaka; Ryosuke Nishio; Tamotsu Mitsuiye; Akira Mizoguchi; Jian Wang; Masayoshi Ishida; Hiroshi Hiai; Akira Matsumori; Nagahiro Minato; Tasuku Honjo
Journal:  Nat Med       Date:  2003-11-02       Impact factor: 53.440

Review 5.  Nature's TRAIL--on a path to cancer immunotherapy.

Authors:  Mark J Smyth; Kazuyoshi Takeda; Yoshihiro Hayakawa; Jacques J Peschon; Marcel R M van den Brink; Hideo Yagita
Journal:  Immunity       Date:  2003-01       Impact factor: 31.745

6.  B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma.

Authors:  Scott E Strome; Haidong Dong; Hideto Tamura; Stephen G Voss; Dallas B Flies; Koji Tamada; Diva Salomao; John Cheville; Fumiya Hirano; Wei Lin; Jan L Kasperbauer; Karla V Ballman; Lieping Chen
Journal:  Cancer Res       Date:  2003-10-01       Impact factor: 12.701

Review 7.  Tumour-cell invasion and migration: diversity and escape mechanisms.

Authors:  Peter Friedl; Katarina Wolf
Journal:  Nat Rev Cancer       Date:  2003-05       Impact factor: 60.716

8.  Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion.

Authors:  Haidong Dong; Scott E Strome; Diva R Salomao; Hideto Tamura; Fumiya Hirano; Dallas B Flies; Patrick C Roche; Jun Lu; Gefeng Zhu; Koji Tamada; Vanda A Lennon; Esteban Celis; Lieping Chen
Journal:  Nat Med       Date:  2002-06-24       Impact factor: 53.440

9.  Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses.

Authors:  Manish J Butte; Mary E Keir; Theresa B Phamduy; Arlene H Sharpe; Gordon J Freeman
Journal:  Immunity       Date:  2007-07-12       Impact factor: 31.745

10.  Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade.

Authors:  Yoshiko Iwai; Masayoshi Ishida; Yoshimasa Tanaka; Taku Okazaki; Tasuku Honjo; Nagahiro Minato
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-06       Impact factor: 11.205

View more
  202 in total

1.  Blockade of programmed death-1 pathway rescues the effector function of tumor-infiltrating T cells and enhances the antitumor efficacy of lentivector immunization.

Authors:  Qifeng Zhou; Haiyan Xiao; Yanjun Liu; Yibing Peng; Yuan Hong; Hideo Yagita; Phillip Chandler; David H Munn; Andrew Mellor; Ning Fu; Yukai He
Journal:  J Immunol       Date:  2010-10-06       Impact factor: 5.422

2.  B7-H1 expression is associated with expansion of regulatory T cells in colorectal carcinoma.

Authors:  Dong Hua; Jing Sun; Yong Mao; Lu-Jun Chen; Yu-Yu Wu; Xue-Guang Zhang
Journal:  World J Gastroenterol       Date:  2012-03-07       Impact factor: 5.742

3.  Inhibitors of B7-CD28 costimulation in urologic malignancies.

Authors:  R Houston Thompson; Eugene D Kwon; James P Allison
Journal:  Immunotherapy       Date:  2009-01       Impact factor: 4.196

4.  B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance.

Authors:  Jang-June Park; Ryusuke Omiya; Yumiko Matsumura; Yukimi Sakoda; Atsuo Kuramasu; Mathew M Augustine; Sheng Yao; Fumihiko Tsushima; Hidehiko Narazaki; Sudarshan Anand; Yingjia Liu; Scott E Strome; Lieping Chen; Koji Tamada
Journal:  Blood       Date:  2010-05-14       Impact factor: 22.113

Review 5.  Beyond cancer vaccines: a reason for future optimism with immunomodulatory therapy.

Authors:  Michael Postow; Margaret K Callahan; Jedd D Wolchok
Journal:  Cancer J       Date:  2011 Sep-Oct       Impact factor: 3.360

Review 6.  The role of lymphocytes in the development and treatment of alopecia areata.

Authors:  Hongwei Guo; Yabin Cheng; Jerry Shapiro; Kevin McElwee
Journal:  Expert Rev Clin Immunol       Date:  2015-09-07       Impact factor: 4.473

Review 7.  Pembrolizumab (Keytruda).

Authors:  Gerry Kwok; Thomas C C Yau; Joanne W Chiu; Eric Tse; Yok-Lam Kwong
Journal:  Hum Vaccin Immunother       Date:  2016-07-11       Impact factor: 3.452

8.  The immune molecular landscape of the B7 and TNFR immunoregulatory ligand-receptor families in head and neck cancer: A comprehensive overview and the immunotherapeutic implications.

Authors:  Yu-Pei Chen; Jian Zhang; Ya-Qin Wang; Na Liu; Qing-Mei He; Xiao-Jing Yang; Ying Sun; Jun Ma
Journal:  Oncoimmunology       Date:  2017-02-16       Impact factor: 8.110

9.  Recurrent Tumor Cell-Intrinsic and -Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation.

Authors:  Chunying Song; Marco Piva; Lu Sun; Aayoung Hong; Gatien Moriceau; Xiangju Kong; Hong Zhang; Shirley Lomeli; Jin Qian; Clarissa C Yu; Robert Damoiseaux; Mark C Kelley; Kimberley B Dahlman; Philip O Scumpia; Jeffrey A Sosman; Douglas B Johnson; Antoni Ribas; Willy Hugo; Roger S Lo
Journal:  Cancer Discov       Date:  2017-09-01       Impact factor: 39.397

10.  A soluble form of CD80 enhances antitumor immunity by neutralizing programmed death ligand-1 and simultaneously providing costimulation.

Authors:  Samuel T Haile; Lucas A Horn; Suzanne Ostrand-Rosenberg
Journal:  Cancer Immunol Res       Date:  2014-04-02       Impact factor: 11.151

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.